熱門資訊> 正文
Tango Therapeutics第一季度GAAP每股收益为-0.35美元，相差0.04美元
2024-05-08 21:52
- Tango Therapeutics press release (NASDAQ:TNGX): Q1 GAAP EPS of -$0.35 misses by $0.04.
- Q1 collaboration revenue was $6.5 million, compared to $5.8 million for the same period in 2023.
- Reports strong cash position of $344 million as of March 31, 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept.
More on Tango Therapeutics
- Seeking Alpha’s Quant Rating on Tango Therapeutics
- Historical earnings data for Tango Therapeutics
- Financial information for Tango Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
